GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Gritstone Bio Inc (NAS:GRTS) » Definitions » ROE %

Gritstone Bio (Gritstone Bio) ROE % : -195.93% (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Gritstone Bio ROE %?

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. Gritstone Bio's annualized net income for the quarter that ended in Dec. 2023 was $-123.27 Mil. Gritstone Bio's average Total Stockholders Equity over the quarter that ended in Dec. 2023 was $62.92 Mil. Therefore, Gritstone Bio's annualized ROE % for the quarter that ended in Dec. 2023 was -195.93%.

The historical rank and industry rank for Gritstone Bio's ROE % or its related term are showing as below:

GRTS' s ROE % Range Over the Past 10 Years
Min: -126.58   Med: -60.72   Max: -39.23
Current: -126.58

During the past 8 years, Gritstone Bio's highest ROE % was -39.23%. The lowest was -126.58%. And the median was -60.72%.

GRTS's ROE % is ranked worse than
81.2% of 1362 companies
in the Biotechnology industry
Industry Median: -44.1 vs GRTS: -126.58

Gritstone Bio ROE % Historical Data

The historical data trend for Gritstone Bio's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Gritstone Bio ROE % Chart

Gritstone Bio Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
ROE %
Get a 7-Day Free Trial -66.63 -69.96 -39.23 -61.88 -124.41

Gritstone Bio Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -81.37 -87.23 -112.62 -167.51 -195.93

Competitive Comparison of Gritstone Bio's ROE %

For the Biotechnology subindustry, Gritstone Bio's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Gritstone Bio's ROE % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Gritstone Bio's ROE % distribution charts can be found below:

* The bar in red indicates where Gritstone Bio's ROE % falls into.



Gritstone Bio ROE % Calculation

Gritstone Bio's annualized ROE % for the fiscal year that ended in Dec. 2023 is calculated as

ROE %=Net Income (A: Dec. 2023 )/( (Total Stockholders Equity (A: Dec. 2022 )+Total Stockholders Equity (A: Dec. 2023 ))/ count )
=-138.49/( (170.781+51.85)/ 2 )
=-138.49/111.3155
=-124.41 %

Gritstone Bio's annualized ROE % for the quarter that ended in Dec. 2023 is calculated as

ROE %=Net Income (Q: Dec. 2023 )/( (Total Stockholders Equity (Q: Sep. 2023 )+Total Stockholders Equity (Q: Dec. 2023 ))/ count )
=-123.272/( (73.982+51.85)/ 2 )
=-123.272/62.916
=-195.93 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Dec. 2023) net income data. ROE % is displayed in the 30-year financial page.


Gritstone Bio  (NAS:GRTS) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-123.272/62.916
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-123.272 / 0.116)*(0.116 / 182.493)*(182.493 / 62.916)
=Net Margin %*Asset Turnover*Equity Multiplier
=-106268.97 %*0.0006*2.9006
=ROA %*Equity Multiplier
=-63.76 %*2.9006
=-195.93 %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Dec. 2023 )
=Net Income/Total Stockholders Equity
=-123.272/62.916
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-123.272 / -123.272) * (-123.272 / -121.884) * (-121.884 / 0.116) * (0.116 / 182.493) * (182.493 / 62.916)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 1 * 1.0114 * -105072.41 % * 0.0006 * 2.9006
=-195.93 %

Note: The net income data used here is four times the quarterly (Dec. 2023) net income data. The Revenue data used here is four times the quarterly (Dec. 2023) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


Gritstone Bio ROE % Related Terms

Thank you for viewing the detailed overview of Gritstone Bio's ROE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Gritstone Bio (Gritstone Bio) Business Description

Traded in Other Exchanges
Address
5959 Horton Street, Suite 300, Emeryville, CA, USA, 94608
Gritstone Bio Inc is a biotechnology company. The company is engaged in developing personalized cancer immunotherapies to fight multiple cancer types and infectious diseases. It is building a pipeline of Immunotherapies product candidates for patients with solid tumors, which includes GRANITE, SLATE, BiSAb, among others.
Executives
Lawrence Corey director C/O GRITSTONE BIO, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE CA 94608
Naiyer Rizvi director C/O ARMO BIOSCIENCES, INC., 575 CHESAPEAKE DRIVE, REDWOOD CITY CA 94063
Elaine V Jones director C/O TARGACEPT, INC., 200 EAST FIRST STREET, SUITE 300, WINSTON-SALEM NC 27101
Clare Fisher director C/O GRITSTONE ONCOLOGY, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE CA 94608
Steve E. Krognes director 863 MITTEN ROAD, SUITE 102, BURLINGAME CA 94010
Shefali Agarwal director C/O EPIZYME, INC., 400 TECHNOLOGY SQUARE, CAMBRIDGE MA 02139
Vassiliki Economides officer: See Remarks C/O KEZAR LIFE SCIENCES, INC., 4000 SHORELINE COURT, SUITE 300, SOUTH SAN FRANCISCO CA 94080
Erin Jones officer: See Remarks C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
James Cho officer: Chief Accounting Officer C/O GRITSTONE ONCOLOGY, INC., 5959 HORTON STREET, SUITE 300, EMERYVILLE CA 94608
Raphael Rousseau officer: See Remarks C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Roman Yelensky officer: See Remarks C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Thomas Woiwode director ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Rahsaan Thompson officer: EVP and General Counsel 233 WILSHIRE BOULEVARD, SUITE 280, SANTA MONICA CA 90401
Vijay Yabannavar officer: See Remarks C/O GRITSTONE ONCOLOGY, INC., 5858 HORTON STREET, SUITE 210, EMERYVILLE CA 94608
Nicholas Simon director 101 MAIN STREET SUITE 1210, CAMBRIDGE MA 02142

Gritstone Bio (Gritstone Bio) Headlines

From GuruFocus